# Alpha HPA Ltd (A4N)

DFS confirms a high margin business

The DFS released by Alpha HPA Ltd (A4N) demonstrates the company is on track to take advantage of the forecasted growth in HPA demand. The announcement of Orica Ltd (ORI.ASX) as the selected reagent supplier allowed Alpha HPA to select the 10Ha site in Gladstone State Development Area. This has eliminated much of the uncertainty on the robustness of the chemical process. Despite increases in initial CapEx (US\$149M to US\$210M), reductions in reagent pricing have decreased annual operating costs by A\$15.1M to A\$127.5Mpa.

### HPA supply deficits expected commencing CY2020

A4N's LT HPA price of US\$25,000/t has been derived from industry research conducted by CRU. CAGR for HPA within the lithium ion battery and LED markets is expected to be 25.4% and 20.4% respectively out to 2028. Deficits in HPA supply are expected as early as this calendar year (CY2020). We believe the strong emphasis on reducing fossil fuel investment and the shift towards greener technologies adds weight to the LT growth in HPA demand.

#### Sales margins remain outstanding

We expect first production to commence in Q1FY23 and have adopted Alpha's expected production ramp up over the first two years. At full capacity, the company will produce 10,000tpa of 4N HPA. We have used a long-term price of US\$20,000 and AISC of US\$6,500/t, thereby giving an AISC margin of US\$13,500/t. The initial capex is expected to be funded through 70:30 debt and equity, with gearing to commence within FY21. We anticipate positive EBITDA to be achieved from FY23, with LT forecasts of A\$196M per annum. Variations in HPA pricing and A\$/US\$ exchange rate have the biggest influence on our valuation and earnings.

### **Highly compelling financials**

The joint collaboration with Orica provides significant confidence on Alpha's chemical process. The company will now continue discussions with offtake parties, progress through the permitting steps and finalising financing. Through technical innovation and highly experienced management, Alpha presents as significant growth opportunity. We maintain a BUY recommendation with a target price of A\$0.74ps.

if you would like to discuss our full research report further please contact us on the details below.

Mining	
12-month rating	
Target Price (A\$ps)	

12-month rating	BUY
Target Price (A\$ps)	0.74
Share Price (A\$ps)	0.13
Upside	496%

BBG: A4N AU

#### Trading data & key metrics

52-week range	0.1 - 0.275
Market Cap:	79
Shares on issue (m):	632
Avg daily volume (k):	1,114
Avg. daily volume -\$m	0.16

#### Directors:

Norman Seckold	CHAIR
Rimas Kairaitis	MD
Peter Nightingale	Director & CFO
Tony Sgro	NED
Justin Werner	NED

#### Substantials:

Regal Funds Management	13.89%
Norman Sekold	10.65%
Budworth Capital Pty Ltd	6.63%
Westpac Asset Management Arm	5.74%



Analyst: Andrew White e: andrew@curranco.com.au t: 02 8188 9499 m: +61 468 348 819 Sales: Kevin Curran e: kevin@curranco.com.au t: 02 8188 9494 m: +61 415 201 002

**PHONE** +61 2 8188 9494 EMAIL andrew@curranco.com.au LOCATION 3 Spring St, Sydney, NSW

# CURRAN&CO

# **Information Disclosure**

Each research analyst of this material certifies that the views expressed in this research material accurately reflect the analyst's personal views about the subject securities and listed corporations. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this material to any of the analyst(s).

# **General Disclosure and Disclaimer**

This research has been prepared by Curran & Co Pty Limited (ABN 40 604 395 226) ("CCPL") for the use of the clients of CCPL and other related bodies corporate (the "Curran & Co Group") and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient, you must not use or disclose the information in this report in any way. CCPL is a holder of an Australian Financial Services License No. 475078.

Nothing in this report should be construed as personal financial product advice for the purposes of Section 766B of the Corporations Act 2001 (Cth). This report does not consider any of your objectives, financial situation or needs. The report may contain general financial product advice and you should therefore consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision.

This research is based on information obtained from sources believed to be reliable and CCPL has made every effort to ensure the information in this report is accurate, but we do not make any representation or warranty that it is accurate, reliable, complete or up to date. The Curran & Co Group accepts no obligation to correct or update the information or the opinions in it. Opinions expressed are subject to change without notice and accurately reflect the analyst(s)' personal views at the time of writing. No member of the Curran & Co Group or its respective employees, agents or consultants accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research.

Nothing in this research shall be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from engaging in any transaction. The Curran & Co Group and/or its associates, including CCPL, officers or employees may have interests in the financial products or a relationship with the issuer of the financial products referred to in this report by acting in various roles including as investment banker, underwriter or dealer, holder of principal positions, broker, director or adviser. Further, they may buy or sell those securities as principal or agent, and as such may affect transactions which are not consistent with the recommendations (if any) in this research. The Curran & Co Group and/or its associates, including CCPL, may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case.

There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment.

The analyst(s) principally responsible for the preparation of this research may receive compensation based on CCPL's overall revenues.

## Copyright

© 2018. All rights reserved. No part of this document may be reproduced or distributed in any manner without the written permission of Curran & Co Pty Limited. Curran & Co Pty Limited specifically prohibits the re-distribution of this document, via the internet or otherwise, and accepts no liability whatsoever for the actions of third parties in this respect.